Patient-derived  	Patient-derived  	 JJ	O
xenografts  	xenografts  	 NN	B-NP
from  	from  	 IN	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
brain  	brain  	 NN	I-NP
metastases  	metastases  	 NNS	I-NP
are  	are  	 VBP	O
valuable  	valuable  	 JJ	O
translational  	translational  	 JJ	B-NP
platforms  	platforms  	 NNS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
personalized  	personalized  	 JJ	O
targeted  	targeted  	 JJ	O
therapy  	therapy  	 NN	O
The  	The  	 DT	O
increasing  	increasing  	 JJ	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
distant  	distant  	 JJ	O
metastases  	metastases  	 NN	B-NP
from  	from  	 IN	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
)  	)  	 -RRB-	O
indicates  	indicates  	 VBZ	O
an  	an  	 DT	O
urgent  	urgent  	 JJ	O
need  	need  	 NN	O
for  	for  	 IN	O
novel  	novel  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
modalities 	modalities 	 NN	I-NP
.  	.  	 .	O
Brain  	Brain  	 NN	B-NP
metastasis  	metastasis  	 NN	I-NP
is  	is  	 VBZ	O
particularly  	particularly  	 RB	O
common  	common  	 JJ	O
in  	in  	 IN	O
NSCLC 	NSCLC 	 NNP	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
severe  	severe  	 JJ	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
on  	on  	 IN	O
clinical  	clinical  	 JJ	B-NP
prognosis 	prognosis 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
molecular  	molecular  	 JJ	B-NP
heterogeneity  	heterogeneity  	 NN	I-NP
of  	of  	 IN	I-NP
NSCLC  	NSCLC  	 NNP	I-NP
and  	and  	 CC	O
availability  	availability  	 NN	O
of  	of  	 IN	O
various  	various  	 JJ	O
targeted  	targeted  	 JJ	O
agents  	agents  	 NNS	O
suggest  	suggest  	 VBP	O
personalized  	personalized  	 VBN	O
therapeutic  	therapeutic  	 JJ	B-NP
approaches  	approaches  	 NNS	I-NP
for  	for  	 IN	O
such  	such  	 JJ	O
brain  	brain  	 NN	B-NP
metastases 	metastases 	 NN	I-NP
,  	,  	 ,	O
further  	further  	 JJ	O
development  	development  	 NN	O
of  	of  	 IN	O
appropriate  	appropriate  	 JJ	O
preclinical  	preclinical  	 JJ	B-NP
models  	models  	 NNS	I-NP
is  	is  	 VBZ	O
needed  	needed  	 VBN	O
to  	to  	 TO	O
validate  	validate  	 VB	O
the  	the  	 DT	O
strategies 	strategies 	 NNS	O
.  	.  	 .	O
We  	We  	 PRP	O
established  	established  	 VBD	O
patient-derived  	patient-derived  	 JJ	B-NP
xenografts  	xenografts  	 NNS	I-NP
( 	( 	 -LRB-	O
PDX 	PDX 	 NNP	B-NP
)  	)  	 -RRB-	O
using  	using  	 VBG	O
NSCLC  	NSCLC  	 NNP	B-NP
brain  	brain  	 NN	I-NP
metastasis  	metastasis  	 VBZ	O
surgical  	surgical  	 JJ	B-NP
samples  	samples  	 NNS	I-NP
and  	and  	 CC	O
elucidated  	elucidated  	 VB	O
their  	their  	 PRP$	O
possible  	possible  	 JJ	O
preclinical  	preclinical  	 NN	B-NP
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
implications  	implications  	 NNS	I-NP
for  	for  	 IN	O
personalized  	personalized  	 JJ	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
NSCLC  	NSCLC  	 NNP	B-NP
brain  	brain  	 NN	I-NP
metastases  	metastases  	 NNS	I-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
34 	34 	 CD	O
)  	)  	 -RRB-	O
showed  	showed  	 VBD	O
a  	a  	 DT	O
significantly  	significantly  	 RB	O
higher  	higher  	 RBR	O
successful  	successful  	 JJ	O
PDX  	PDX  	 NNP	B-NP
establishment  	establishment  	 NN	I-NP
rate  	rate  	 NN	I-NP
than  	than  	 IN	O
primary  	primary  	 JJ	B-NP
specimens  	specimens  	 NNS	I-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
64 	64 	 CD	O
;  	;  	 :	O
74 	74 	 CD	O
%  	%  	 NN	O
vs.  	vs.  	 IN	O
23 	23 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
PDXs  	PDXs  	 JJ	B-NP
derived  	derived  	 NN	I-NP
from  	from  	 IN	O
NSCLC  	NSCLC  	 NNP	B-NP
brain  	brain  	 NN	I-NP
metastases  	metastases  	 NNS	I-NP
recapitulated  	recapitulated  	 VBP	O
the  	the  	 DT	O
pathologic 	pathologic 	 NN	B-NP
,  	,  	 ,	O
genetic 	genetic 	 JJ	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
functional  	functional  	 JJ	B-NP
properties  	properties  	 NNS	I-NP
of  	of  	 IN	O
corresponding  	corresponding  	 JJ	O
parental  	parental  	 JJ	O
tumors 	tumors 	 NNS	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
tumor  	tumor  	 NN	B-NP
spheres  	spheres  	 VBZ	I-NP
established  	established  	 VBN	O
in  	in  	 IN	O
vitro  	vitro  	 NN	B-NP
from  	from  	 IN	O
the  	the  	 DT	O
xenografts  	xenografts  	 NN	B-NP
under  	under  	 IN	O
serum-free  	serum-free  	 JJ	B-NP
conditions  	conditions  	 NNS	I-NP
maintained  	maintained  	 VBD	O
their  	their  	 PRP$	O
in  	in  	 FW	O
vivo  	vivo  	 FW	B-NP
brain  	brain  	 FW	I-NP
metastatic  	metastatic  	 FW	I-NP
potential 	potential 	 NN	I-NP
.  	.  	 .	O
Differential  	Differential  	 JJ	B-NP
phenotypic  	phenotypic  	 NN	I-NP
and  	and  	 CC	O
molecular  	molecular  	 JJ	B-NP
responses  	responses  	 NNS	I-NP
to  	to  	 TO	O
20  	20  	 CD	O
targeted  	targeted  	 JJ	O
agents  	agents  	 NNS	O
could  	could  	 MD	O
subsequently  	subsequently  	 RB	O
be  	be  	 VB	O
screened  	screened  	 VBN	O
in  	in  	 IN	O
vitro  	vitro  	 NNS	B-NP
using  	using  	 VBG	O
these  	these  	 DT	O
NSCLC  	NSCLC  	 NNP	B-NP
PDXs  	PDXs  	 NNP	I-NP
derived  	derived  	 VBD	O
from  	from  	 IN	O
brain  	brain  	 NN	B-NP
metastases 	metastases 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
PDX  	PDX  	 NNP	B-NP
establishment  	establishment  	 NN	I-NP
from  	from  	 IN	O
primary  	primary  	 JJ	B-NP
NSCLCs  	NSCLCs  	 NN	I-NP
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
influenced  	influenced  	 VBN	O
by  	by  	 IN	O
histologic  	histologic  	 JJ	B-NP
subtype 	subtype 	 NN	I-NP
,  	,  	 ,	O
clinical  	clinical  	 JJ	B-NP
aggressiveness 	aggressiveness 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
genetic  	genetic  	 JJ	B-NP
alteration  	alteration  	 JJ	I-NP
status 	status 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
brain  	brain  	 NN	O
metastases  	metastases  	 VBZ	O
exhibited  	exhibited  	 VBN	O
consistently  	consistently  	 RB	O
adequate  	adequate  	 JJ	O
in  	in  	 IN	O
vivo  	vivo  	 JJ	B-NP
tumor  	tumor  	 NN	I-NP
take  	take  	 VB	O
rate  	rate  	 NN	O
and  	and  	 CC	O
in  	in  	 IN	O
vitro  	vitro  	 JJ	B-NP
tumor  	tumor  	 NN	I-NP
sphere  	sphere  	 NN	I-NP
formation  	formation  	 NN	I-NP
capacity 	capacity 	 NN	I-NP
,  	,  	 ,	O
regardless  	regardless  	 RB	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
molecular  	molecular  	 JJ	B-NP
conditions 	conditions 	 NNS	I-NP
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
PDXs  	PDXs  	 JJ	O
from  	from  	 IN	O
NSCLC  	NSCLC  	 NNP	B-NP
brain  	brain  	 NN	I-NP
metastases  	metastases  	 NNS	I-NP
may  	may  	 MD	O
better  	better  	 RB	O
represent  	represent  	 VB	O
the  	the  	 DT	O
heterogeneous  	heterogeneous  	 NN	O
advanced  	advanced  	 VBD	B-NP
NSCLC  	NSCLC  	 NNP	I-NP
population  	population  	 NN	I-NP
and  	and  	 CC	O
could  	could  	 MD	O
be  	be  	 VB	O
utilized  	utilized  	 VBN	O
as  	as  	 IN	O
preclinical  	preclinical  	 JJ	B-NP
models  	models  	 NNS	I-NP
to  	to  	 TO	O
meet  	meet  	 VB	O
unmet  	unmet  	 JJ	B-NP
clinical  	clinical  	 NN	I-NP
needs  	needs  	 VBZ	O
such  	such  	 JJ	O
as  	as  	 IN	O
drug  	drug  	 NN	B-NP
screening  	screening  	 NN	I-NP
for  	for  	 IN	O
personalized  	personalized  	 JJ	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
